1. Home
  2. BAFN vs ACET Comparison

BAFN vs ACET Comparison

Compare BAFN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BAFN
  • ACET
  • Stock Information
  • Founded
  • BAFN 1999
  • ACET 1947
  • Country
  • BAFN United States
  • ACET United States
  • Employees
  • BAFN N/A
  • ACET N/A
  • Industry
  • BAFN Savings Institutions
  • ACET Biotechnology: Pharmaceutical Preparations
  • Sector
  • BAFN Finance
  • ACET Health Care
  • Exchange
  • BAFN Nasdaq
  • ACET Nasdaq
  • Market Cap
  • BAFN 70.2M
  • ACET 70.3M
  • IPO Year
  • BAFN N/A
  • ACET N/A
  • Fundamental
  • Price
  • BAFN $16.61
  • ACET $0.72
  • Analyst Decision
  • BAFN
  • ACET Buy
  • Analyst Count
  • BAFN 0
  • ACET 6
  • Target Price
  • BAFN N/A
  • ACET $6.00
  • AVG Volume (30 Days)
  • BAFN 10.6K
  • ACET 324.2K
  • Earning Date
  • BAFN 04-24-2025
  • ACET 03-06-2025
  • Dividend Yield
  • BAFN 1.90%
  • ACET N/A
  • EPS Growth
  • BAFN 134.19
  • ACET N/A
  • EPS
  • BAFN 2.62
  • ACET N/A
  • Revenue
  • BAFN $83,769,000.00
  • ACET N/A
  • Revenue This Year
  • BAFN N/A
  • ACET N/A
  • Revenue Next Year
  • BAFN N/A
  • ACET N/A
  • P/E Ratio
  • BAFN $6.26
  • ACET N/A
  • Revenue Growth
  • BAFN 10.60
  • ACET N/A
  • 52 Week Low
  • BAFN $10.40
  • ACET $0.69
  • 52 Week High
  • BAFN $19.75
  • ACET $2.40
  • Technical
  • Relative Strength Index (RSI)
  • BAFN 37.70
  • ACET 37.26
  • Support Level
  • BAFN $16.00
  • ACET $0.74
  • Resistance Level
  • BAFN $19.00
  • ACET $0.91
  • Average True Range (ATR)
  • BAFN 0.99
  • ACET 0.06
  • MACD
  • BAFN -0.34
  • ACET -0.00
  • Stochastic Oscillator
  • BAFN 16.27
  • ACET 12.61

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: